Clinical Trial Update: Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for Encochleated oral amphotericin for cryptococcal meningitis (EnACT) in Phase 1 and Phase 2, with completed status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cryptococcal Meningitis

Drugs mentioned

• Encochleated oral amphotericin (amphotericin)

Snippet

Sponsor: Matinas BioPharma Nanotechnologies, Inc. | Conditions: Cryptococcal Meningitis | Phase 1, Phase 2 | Status: COMPLETED